Tamoxifen generics
Executive Summary
Seven generic manufacturers are approved to launch tamoxifen (equivalent to AstraZeneca's Nolvadex) on Feb. 21. Barr, which marketed an "authorized" generic for a decade until the agreement expired in August, is among those with approved ANDAs. AstraZeneca is already marketing its own generic version (1"The Pink Sheet" Feb. 3, p. 13). Ivax, Mylan, Teva and Roxane Labs 10 mg tablets (60-count) will be priced at $113.10 to $113.77 AWP. AstraZeneca AWP for the generic is $116.98, while branded Nolvadex carries an AWP of $126.41, according to First DataBank's Price Alert. Barr says its price will be below what it offered under the AstraZeneca licensing deal ($121.59 AWP). Andrx also received approval, but says it has no plans to launch due to the number of competitors...
You may also be interested in...
AstraZeneca Self-Markets Nolvadex Generic; Zoladex Settlement Near
AstraZeneca is marketing its own generic version of Nolvadex (tamoxifen) to protect the company from claims that it is exploiting cancer patients in the final months of exclusivity for the drug
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.